Galera Therapeutics (GRTX) Stock Price, News & Analysis

Company Overview

Galera Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania. The company focuses on developing precision medicines designed to address oxidative stress and inflammation in pulmonary and rare diseases. Galera’s proprietary platform centers on small-molecule prodrugs of glutathione and related thiol compounds intended to enhance intracellular antioxidant defenses.

Galera’s lead product candidate is an inhaled glutathione prodrug currently in early-stage clinical trials for acute lung injury and acute respiratory distress syndrome. In addition to its pulmonary programs, the company is advancing research into supportive therapies for oncology patients and exploring additional indications where modulation of oxidative stress may offer therapeutic benefit. Galera employs both inhalation and systemic delivery approaches to optimize tissue targeting and pharmacokinetics.

Founded in 2013, Galera has secured funding through private financings and a public listing on the NASDAQ under the symbol GRTX. The company collaborates with academic research centers and clinical investigators in the United States, and it is positioning itself for potential international partnerships to expand development and commercialization efforts. Under the guidance of a team of seasoned biotechnology executives and drug development scientists, Galera aims to translate its redox-modulating platform into new treatments for patients with high-unmet-need respiratory and systemic conditions.

Key Stats

• Today's Range: $0.09 to $0.10
• 50-Day Range: $0.03 to $0.10
• 52-Week Range: $0.02 to $0.15
• Volume: 11,033 shs
• Average Volume: 242,967 shs
• Market Capitalization: $6.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GRTX Stock Analysis - Frequently Asked Questions

How have GRTX shares performed this year?

Galera Therapeutics' stock was trading at $0.0220 on January 1st, 2026. Since then, GRTX stock has increased by 320.5% and is now trading at $0.0925.

How were Galera Therapeutics' earnings last quarter?

Galera Therapeutics, Inc. (NASDAQ:GRTX) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15.

When did Galera Therapeutics IPO?

Galera Therapeutics (GRTX) raised $75 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Galera Therapeutics?

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Energy Transfer (ET), Plug Power (PLUG), NGL Energy Partners (NGL), Universal Display (OLED), Verastem (VSTM) and Alerian MLP ETF (AMLP).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 5/05/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRTX
• CIK: 1563577
• Web: www.galeratx.com
• Phone: 610-725-1500
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.64
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -99.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.74
• Quick Ratio: 9.74

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.41) per share
• Price / Book: -0.04

Miscellaneous

• Outstanding Shares: 75,462,000
• Free Float: 47,375,000
• Market Cap: $6.98 million
• Optionable: Optionable
• Beta: 2.64